BR112015012102A2 - utilização de um éster de dha para o tratamento profilático e/ou curativo da drepanocitose - Google Patents

utilização de um éster de dha para o tratamento profilático e/ou curativo da drepanocitose

Info

Publication number
BR112015012102A2
BR112015012102A2 BR112015012102A BR112015012102A BR112015012102A2 BR 112015012102 A2 BR112015012102 A2 BR 112015012102A2 BR 112015012102 A BR112015012102 A BR 112015012102A BR 112015012102 A BR112015012102 A BR 112015012102A BR 112015012102 A2 BR112015012102 A2 BR 112015012102A2
Authority
BR
Brazil
Prior art keywords
drepanocytosis
prophylactic
curative treatment
dha ester
ester
Prior art date
Application number
BR112015012102A
Other languages
English (en)
Inventor
Lantoine-Adam Frédérique
Caubere Jean-Paul
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112015012102A2 publication Critical patent/BR112015012102A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "utilização de um éster de dha para o tratamento profilático e/ou curativo da drepanocitose". a presente invenção refere-se a um éster do ácido docosa-hexanoico com um álcool escolhido dentre o grupo constituído pelo nicotinol, o pantenol, o inositol, o isossorbida e o isossorbida mononitrato, ou um de seus sais farmaceuticamente aceitáveis, enantiômeros, diastereoisômeros, ou sua mistura, aí compreendidas as misturas racêmicas, para sua utilização a título de medicamento profilático e/ou curativo da drepanocitose.
BR112015012102A 2012-11-27 2013-11-27 utilização de um éster de dha para o tratamento profilático e/ou curativo da drepanocitose BR112015012102A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1261291A FR2998479B1 (fr) 2012-11-27 2012-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose
PCT/EP2013/074863 WO2014083059A1 (fr) 2012-11-27 2013-11-27 Utilisation d'un ester de dha pour le traitement prophylactique et/ou curatif de la drepanocytose

Publications (1)

Publication Number Publication Date
BR112015012102A2 true BR112015012102A2 (pt) 2017-07-11

Family

ID=47714308

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012102A BR112015012102A2 (pt) 2012-11-27 2013-11-27 utilização de um éster de dha para o tratamento profilático e/ou curativo da drepanocitose

Country Status (10)

Country Link
US (1) US20150306056A1 (pt)
EP (1) EP2925311A1 (pt)
BR (1) BR112015012102A2 (pt)
FR (1) FR2998479B1 (pt)
IL (1) IL238954A0 (pt)
MA (1) MA38113A1 (pt)
MX (1) MX2015006685A (pt)
TN (1) TN2015000199A1 (pt)
WO (1) WO2014083059A1 (pt)
ZA (1) ZA201503808B (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946457B2 (en) * 2001-04-06 2005-09-20 The Trustees Of Columbia University In The City Of New York Methods of treating sickle cell disease
WO2007075841A1 (en) * 2005-12-20 2007-07-05 Cenestra, Llc Omega 3 fatty acid formulations
FR2902659A1 (fr) * 2006-06-23 2007-12-28 Pierre Fabre Medicament Sa Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
FR2949063B1 (fr) * 2009-08-11 2011-09-30 Pf Medicament Composition pharmaceutique comprenant un ester de dha destinee a etre administree par voie parenterale
FR2963790B1 (fr) * 2010-08-11 2012-09-28 Pf Medicament Docosahexaeneoate de panthenyle et son utilisation dans le traitement et la prevention des maladies cardiovasculaires

Also Published As

Publication number Publication date
MX2015006685A (es) 2015-08-20
IL238954A0 (en) 2015-07-30
US20150306056A1 (en) 2015-10-29
WO2014083059A1 (fr) 2014-06-05
FR2998479B1 (fr) 2017-04-28
TN2015000199A1 (fr) 2016-10-03
ZA201503808B (en) 2016-07-27
EP2925311A1 (fr) 2015-10-07
MA38113A1 (fr) 2016-09-30
FR2998479A1 (fr) 2014-05-30

Similar Documents

Publication Publication Date Title
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BR112015020941A2 (pt) uso de derivados de pirazolopirimidina para o tratamento de distúrbios relacionados a pi3kdelta
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
GT201300243A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
EA201490300A1 (ru) 4-имидазопиридазин-1-ил-бензамиды и 4-имидазотриазин-1-ил-бензамиды в качестве btk-ингибиторов
EA201491857A1 (ru) АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
EA201591957A1 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CO6382089A2 (es) Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
TR201902057T4 (tr) Tetrasiklin bileşikleri.
GT201400161A (es) Fenilimidazopirazoles sustituidos y su uso
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
BR112014029838A2 (pt) formas no estado sólido de n-((s)-2,3-di-hidróxi-propil)-3-(2-flúor-4-iodo-fenilamino)- isonicotinamida
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
EA201591180A1 (ru) Составы ингибитора lfa-1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.